Skip to main content
. 2019 May 2;25(4):360–365. doi: 10.3350/cmh.2019.0022

Figure 1.

Figure 1.

Sustained virological response (SVR) rates to sofosbuvir/velapatasvir/voxilaprevir in previous direct acting antiviral fauilures. Sofosbuvir/velpatasvir/voxilaprevir for the re-treatment of direct acting antiviral failures. SVR12, sustained virological response at week 12.